Back to Healio The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence ...

This decision suggests that Winrevair has shown significant benefits for patients with pulmonary arterial hypertension, which was initially observed in the STELLAR trial. Graybosch believes that ...

Winrevair generated $200M Get the Real Story Behind Every Major Earnings Report Merck reported adjusted EPS of $1.72, up from $0.03 a year ago and beating the consensus of $1.62. Lower charges for ...

Chief Executive Robert Davis attributed growth in 2024 to Keytruda, the launch of Winrevair and performance in the animal health business. Winrevair launched in the U.S. in the second quarter.

After slow rollout, Merck's Winrevair poised for 'strong uptake' in 2025: Leerink Additionally, Merck continues to maintain faith in Gardasil’s future sales prospects in China overall ...

The newly approved Winrevair (sotatercept) for adults with pulmonary arterial hypertension generated sales of $200 million. Guidance: Merck expects fiscal year 2025 sales of $64.1 billion-$65.6 ...

Higher sales in the cardiovascular franchise, according to Merck, reflecting the successful launch of WINREVAIR, as well as higher sales of certain hospital acute care products, particularly ...

Chief Executive Robert Davis attributed growth in 2024 to Keytruda, the launch of hypertension drug Winrevair and performance in the animal-health business. Winrevair launched in the U.S. in the ...

the successful launch of WINREVAIR and strong performance of our Animal Health business,” said Robert M. Davis, chairman and chief executive officer, Merck (MRK). “We’re continuing to ...